GnRH Agonist Shows Protection Against Early Menopause in Breast Cancer
(HealthDay News) — For patients with breast cancer, use of the gonadotropin-releasing hormone agonist, goserelin, protects against ovarian failure, according to a study published in the March 5 issue of the New England Journal of Medicine.
Halle C.F. Moore, MD, from the Cleveland Clinic Foundation, and colleagues randomized 257 premenopausal women with operable hormone-receptor-negative breast cancer to receive standard chemotherapy with or without goserelin. Two hundred eighteen patients were eligible and could be assessed; 135 had complete primary end point data.
The researchers found that the ovarian failure rate was 8 and 22% in the goserelin and chemotherapy-alone groups, respectively (odds ratio, 0.30; two-sided P=0.04). Results consistent with the main findings were obtained in sensitivity analyses performed due to missing primary end point data. Among the 218 women who were evaluated, pregnancy occurred in 21% of women in the goserelin group and 11% in the chemotherapy-alone group (P=0.03). Improved disease-free and overall survival were also seen in the goserelin group (P=0.04 and P=0.05).
"Administration of goserelin with chemotherapy appeared to protect against ovarian failure, reducing the risk of early menopause and improving prospects for fertility," the authors write.